Clinical Trial Evidence: What the Data Shows
What's Better Wegovy or Mounjaro: Understanding the Clinical Evidence
When evaluating what's better between Wegovy or Mounjaro for weight loss results in the UK, the clinical trial evidence provides valuable insights into each treatment's efficacy profile. Wegovy (semaglutide) demonstrated substantial weight loss results in the landmark STEP trial programme, with patients achieving an average of ~clinically studied weight loss at 68 weeks when combined with reduced-calorie diet and increased physical activity. The SELECT cardiovascular outcomes trial further showed a 20% reduction in major cardiovascular events, highlighting Wegovy's broader health benefits beyond weight management.
Mounjaro (tirzepatide) operates through a dual GIP and GLP-1 receptor agonist mechanism, whilst Wegovy works specifically as a GLP-1 receptor agonist. Both treatments require prescription-only medicine status and clinical assessment to ensure appropriate prescribing. The choice between these medications often depends on individual patient factors, tolerance profiles, and specific clinical circumstances that qualified prescribers evaluate during consultation.
Wegovy vs Mounjaro Pricing: UK Treatment Costs Comparison
Understanding the cost implications when deciding what's better between Wegovy or Mounjaro involves examining both single pen prices and bundle options available through EverydayMeds. Wegovy single pens range from £79.99 for the 0.25mg starter dose to £209.99 for the 2.4mg maintenance dose, with new customers applying code FIRST40 at checkout. Our Getting Started bundles, such as the Intro Duo (0.25mg & 0.5mg) at £169.99, provide convenient dose escalation without multiple orders.
For patients requiring consistent maintenance dosing, our Stay Steady bundles offer practical solutions like the Consistency 2.4mg (×2) at £419.99 for two months of treatment. The Ultimate Stability Trio provides three months of 2.4mg maintenance supply for £649.99, ensuring uninterrupted treatment continuation. Returning customers can use code DOSE25 at checkout, whilst all orders include next-day cold-chain delivery from our GPhC-registered facility #9012878.
STEP Trial Results: Evidence-Based Weight Loss Outcomes
The STEP clinical trial programme provides robust evidence for Wegovy's efficacy in weight management applications. STEP 1 enrolled 1,961 adults with obesity, demonstrating ~15% average weight loss versus ~2.4% with placebo at 68 weeks (Wilding et al., NEJM, 2021). STEP 3 combined Wegovy with intensive behavioural therapy, achieving ~clinically studied weight loss in the intervention group.
Long-term sustainability data from STEP 5 showed ~clinically studied weight loss maintained at 2 years, whilst STEP 2 specifically evaluated patients with type 2 diabetes, achieving ~clinically studied weight loss. These results were obtained when Wegovy was used alongside a reduced-calorie diet and increased physical activity, emphasising the importance of comprehensive lifestyle modifications in treatment success.
How Wegovy Works: GLP-1 Mechanism for Weight Management
Wegovy functions as a GLP-1 receptor agonist, mimicking the action of naturally occurring incretin hormones that regulate appetite and glucose metabolism. The medication binds to GLP-1 receptors in the brain's appetite control centres, reducing hunger signals and promoting satiety after smaller meal portions. This mechanism helps patients feel satisfied with reduced caloric intake, supporting sustainable weight loss when combined with dietary modifications. The once-weekly injection schedule using Novo Nordisk's FlexTouch pen system provides consistent therapeutic levels throughout the week. Dose escalation from 0.25mg to the maintenance dose of 2.4mg occurs gradually over 16 weeks, allowing patients to adjust to the medication whilst minimising potential gastrointestinal side effects.
EverydayMeds Ordering Process: From Assessment to Delivery
Our streamlined process begins with a comprehensive 3-minute online clinical assessment covering medical history, current medications, and weight management goals relevant to determining what's better between Wegovy or Mounjaro for individual patients. Qualified prescribers review applications within 3 working days (or 24 hours with express service), ensuring appropriate clinical oversight for this prescription-only medicine. Upon approval, orders are dispatched via next-day delivery using temperature-controlled cold-chain logistics to maintain medication integrity. Our GPhC-registered pharmacy operates under stringent quality standards, with all Wegovy supplies sourced directly from Novo Nordisk through licensed distribution channels. Patient support continues throughout treatment, with clinical queries addressed by our qualified team and repeat prescriptions managed seamlessly through the online portal.
Storage Requirements: Practical Considerations for Daily Use
Wegovy requires refrigerated storage at 2–8°C before first use, but offers significant practical advantages with 6 weeks of room temperature stability below 30°C once removed from refrigeration. This storage flexibility proves particularly valuable for travel situations or workplace administration compared to Mounjaro's 21-day room temperature limit. The FlexTouch pen design incorporates dose confirmation features and clear dosage displays, whilst the once-weekly injection schedule reduces administration burden. Patients progress through mandatory dose escalation: 0.25mg (weeks 1–4), 0.5mg (weeks 5–8), 1mg (weeks 9–12), 1.7mg (weeks 13–16), before reaching 2.4mg maintenance dosing. Each pen contains four weekly doses, with clear markings to prevent dosing errors during the titration phase.
UK Weight Loss Results: Real-World Clinical Application
When considering what's better between Wegovy or Mounjaro for UK patients, real-world evidence complements clinical trial data in demonstrating treatment effectiveness. NICE guidance TA875 recommends Wegovy for eligible patients with BMI ≥30 or BMI ≥27 with weight-related comorbidities, typically within specialist weight management services. UK prescribing data shows consistent adoption among healthcare providers, with patients achieving clinically meaningful weight loss when treatment combines with structured dietary support.
The medication's approval for adolescents aged 12 years and above (body weight >60kg) expands treatment options for younger patients with significant obesity. However, individual results vary considerably, and the decision between Wegovy and Mounjaro requires personalised clinical assessment considering patient factors, contraindications, and treatment preferences that qualified prescribers evaluate comprehensively.
Making Your Choice: Personalised Treatment Selection
Determining what's better between Wegovy or Mounjaro ultimately depends on individual clinical circumstances that extend beyond published trial data. Both medications are available through EverydayMeds following thorough clinical assessment, with qualified prescribers helping patients navigate treatment options based on medical history, concurrent medications, and specific health goals. Start your assessment today using code FIRST40 for new customers, with next-day delivery ensuring prompt treatment initiation once approved. Our clinical team remains available throughout your weight management journey, providing ongoing support and monitoring to optimise treatment outcomes.
Reviewed by the EverydayMeds Clinical Team · GPhC #9012878 · Last updated February 2026
